Signed in as:
filler@godaddy.com
January 17, 2025
Naason Newsletter 1/2025
Start the New Year with Breakthrough Preclinical Insights.
New in vivo models aimed at Cardiac Diseases
Naason Science Recognizes World Cardiology Day
Seoul and Osong, Republic of South Korea September 29th, 2024 - Naason Science Inc. (Republic of South Korea), a preclinical contract, and collaborative, research organization announces the release of newly validated models for complete atro-ventricular block (CAVB) and pacemaker-induced cardiomyopathy (PICM).
The models are available in both rodents (rats) and in pigs. The inclusion of these validated models is the product of 3 years of internal and collaborative research and development by Naason’s staff of scientists and technicians. The models are perfectly suited for the testing of new gene therapies as well as devices and drugs aimed at alleviating the underlying symptoms accompanied by these complex conditions.
The models involve induction of the deficit, real-time ECG measurement, and subsequent telemetric tracking of ECG post-operatively and molecular and histopathological analysis. The porcine model includes all of the above with the additional possibility of echocardiography to track changes and to observe indications of efficacy.
For additional information please contact info@naasonscience.com
Naason Exhibiting at Neuroscience 2024
We are looking forward meeting you in Chicago! Welcome to visit our Booth #355!
Naason presenting at ARVO 2024 Annual Meeting
Title: Validation of the two-stage laser mouse model of subretinal fibrosis and the therapeutic effect of afliberceptn
Session Date/Times: May 5, 2024 from 1:00 PM to 2:45 PM (Sunday)
Presentation Number - Posterboard Number: 755 - B0256
Session Number: 135
Session Title: AMD: Mechanisms and preclinical studies
Osong, South Korea 2023-09-01
Exhibiting at AFLAS 2023
Naason Science will be exhibiting at AFLAS 2023 Congress at Jeju International Convention Center (Jeju ICC) in Jeju island on September 13 to 15, 2023.
We will be located on the Third Floor booth number 26.
Sponsoring 15th World Congress on Endometriosis
May 7, 2023 - Osong, Republic of South Korea; Edinburgh, United Kingdom
Naason Science Ltd. shows presence and support for those suffering from endometriosis by attending the World Congress of Endometriosis in Edinburgh, Scotland.
Women’s health and genitourinary health issues remain a largely unmet need on a global scale. Naason Science, its scientific and technical staff, along with its comprehensive preclinical drug development capabilities are committed to continued support for this community through preclinical research.
Recently in Edinburgh at the World Endometriosis Congress Naason Science attended workshops and presentations as well as chairing a session of presentations outlining some of the newer experimental drug treatments aimed at endometriosis.
Naason Science’s CEO Dr Larry Chong Park teamed up with Professor Christian Becker (Oxford University) to chair a session on potential new therapies for endometriosis. It was a great opportunity to hear the thoughts on what may be on the horizon for the treatment of endometriosis in the future. The presentations were thoroughly enjoyable and thought provoking.
While addressing the responses as well as the drug discovery community present during the sessions Dr Larry Park, Naason Science CEO said, “we are very happy to be able to receive and comment on the information provided by those presenting the data for these possible future therapies aimed at endometriosis. Despite my 25 years as a drug discoverer, I am always interested in how others see the route forward for certain technologies. It is obvious to us at Naason that the world endometriosis community is committed to finding new ways to tackle this potentially debilitating disease and this only makes Naason just as committed. Therefore, it is important that we remain in touch with developers as well as those advocating for increasing the amount of research and research funding into this disease area. The work that Naason continues to do the area of endometriosis is currently unmat5hced in the preclinical sector and we will increase this over the coming year.”
Naason science thanks all of the attendees with whom we met as well as all of those who presented their data and ideas at the WCE in Edinburgh.
Professor Christian Becker from Oxford University and Naason Science’s CEO Dr Larry Chong Park
Naason Science honored with the Presidential Commendation
December 16, 2022 - Naason Science won the Presidential Commendation in the Entrepreneurship Division in the field of Entrepreneurship Revitalization at the '2022 Venture Startup Promotion Awards Ceremony'.
The Venture Startup Promotion Awards Ceremony, which was held on the 15th of December, is an annual event hosted by the Ministry of SMEs and Startups to discover and encourage excellent venture companies and start-ups that lead innovative growth. Awards were given to ventures, start-ups, investment, and support institutions that contributed to job creation and industrial development this year.
Article: http://www.jbnews.com/news/articleView.html?idxno=1379318
NEW Publication: Emerging Role of Translational Digital Biomarkers Within Home Cage Monitoring Technologies in Preclinical Drug Discovery and Development
While working with 14 different international institutions is rewarding in itself, our collaboration being recognized by Frontiers is a source of pride and joy.
Access the article yourself and learn more about the emerging role of translational digital biomarkers within home cage monitoring technologies in preclinical drug discovery and development!
Naason Science developing models of PTSD
Published 2021-07-16
PTSD is a serious condition that can lead to intense fear, anxiety and depression. Current medication is unspecific, ineffective and has a vast number of side effects (sedation, abuse potential, sexual dysfunction). As a result, many people continue to suffer from PTSD in spite of current treatment options, indicating a critical need for new treatments.
One limiting factor in the development of treatment for PTSD is the lack of valid, translational models. Naason Science has been developing models of PTSD in the rat and has initiated a development program in a larger animal - the minipig, based on a multi-faceted prolonged stress paradigm, so as to test the efficacy of new compounds.
Bio Spectator, published 2020-12-08
The potential of Naason Science - a global professional CRO
Naason Science is a CNS CRO established in Korea in 2017. Naason Science was established to target the global market from the beginning, and its partners are diverse not only in Korea but also in Europe, including Germany and the Netherlands, and Japan.
Naason Science 2020-04-16
Endometriosis Modelling platform
The model can be used as a biochemical and histopathological model and also exhibits evoked pain signals and non evoked signals of pain, as well as anxiety and depression.